Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis

Rik J. U. Lories, Inge Derese, Cosimo De Bari, Frank P. Luyten

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

OBJECTIVE: To study the relationship between inflammation and remodeling by inhibiting tumor necrosis factor alpha (TNFalpha) in male DBA/1 mice with spontaneous arthritis, a model of spondylarthritis (SpA). METHODS: TNFalpha was inhibited using etanercept, a soluble TNF receptor. The efficacy of the dose used (25 micro g/mouse) was confirmed in methylated bovine serum albumin (mBSA)-induced monarthritis, a model of inflammation-driven joint destruction. Male DBA/1 mice with spontaneous arthritis were caged together from the age of 10 weeks onward and were treated twice weekly with etanercept. The incidence and clinical severity of disease were recorded. Mice were killed at age 25 weeks, and histomorphologic analysis was performed. The presence of TNFalpha, NF-kappaB, and Smad signaling was studied using immunohistochemistry. Entheseal endochondral bone formation was modeled using micromass cultures of periosteal cells. RESULTS: Etanercept inhibited mouse TNFalpha in vitro and in vivo. Etanercept treatment of mBSA-induced arthritis had a significant effect on the severity of disease. Etanercept did not affect the incidence or severity of spontaneous arthritis. Pathologic analysis revealed no differences between etanercept-treated and phosphate buffered saline-treated mice. TNFalpha-positive cells were observed in the synovium, in vessel-associated cells, in fibrocartilage, and in new cartilage. Activation of Smad signaling was observed in earlier stages of disease than was active NF-kappaB signaling. TNFalpha inhibited chondrogenesis in the micromass model. CONCLUSION: Inhibition of TNF did not affect the severity and incidence of joint ankylosis in a mouse model of SpA. Therefore, the process of entheseal ankylosis may be independent of TNF. New tissue formation in SpA could be considered an additional and specific therapeutic target.
Original languageEnglish
Pages (from-to)489-497
Number of pages9
JournalArthritis & Rheumatism
Volume56
Issue number2
Early online date30 Jan 2007
DOIs
Publication statusPublished - 1 Feb 2007

Fingerprint

Spondylarthritis
Tumor Necrosis Factor-alpha
Joints
Inflammation
Arthritis
Ankylosis
Inbred DBA Mouse
NF-kappa B
Incidence
Fibrocartilage
Chondrogenesis
Synovial Membrane
Tumor Necrosis Factor Receptors
Osteogenesis
Cartilage
Etanercept
Cell Culture Techniques
Immunohistochemistry
Phosphates
Therapeutics

Keywords

  • animals
  • ankylosis
  • antibodies
  • antirheumatic agents
  • bone morphogenetic proteins
  • cells, cultured
  • disease models, animal
  • disease progression
  • immunoglobulin G
  • inflammation
  • joints
  • male
  • mice
  • mice, inbred DBA
  • NF-kappa B
  • osteogenesis
  • receptors, tumor necrosis factor
  • severity of illness index
  • smad proteins
  • spondylarthritis
  • tumor necrosis factor-alpha

Cite this

Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. / Lories, Rik J. U.; Derese, Inge; De Bari, Cosimo; Luyten, Frank P.

In: Arthritis & Rheumatism, Vol. 56, No. 2, 01.02.2007, p. 489-497.

Research output: Contribution to journalArticle

Lories, Rik J. U. ; Derese, Inge ; De Bari, Cosimo ; Luyten, Frank P. / Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. In: Arthritis & Rheumatism. 2007 ; Vol. 56, No. 2. pp. 489-497.
@article{17abdc6d81ac4222ab498a46abb2f0ed,
title = "Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis",
abstract = "OBJECTIVE: To study the relationship between inflammation and remodeling by inhibiting tumor necrosis factor alpha (TNFalpha) in male DBA/1 mice with spontaneous arthritis, a model of spondylarthritis (SpA). METHODS: TNFalpha was inhibited using etanercept, a soluble TNF receptor. The efficacy of the dose used (25 micro g/mouse) was confirmed in methylated bovine serum albumin (mBSA)-induced monarthritis, a model of inflammation-driven joint destruction. Male DBA/1 mice with spontaneous arthritis were caged together from the age of 10 weeks onward and were treated twice weekly with etanercept. The incidence and clinical severity of disease were recorded. Mice were killed at age 25 weeks, and histomorphologic analysis was performed. The presence of TNFalpha, NF-kappaB, and Smad signaling was studied using immunohistochemistry. Entheseal endochondral bone formation was modeled using micromass cultures of periosteal cells. RESULTS: Etanercept inhibited mouse TNFalpha in vitro and in vivo. Etanercept treatment of mBSA-induced arthritis had a significant effect on the severity of disease. Etanercept did not affect the incidence or severity of spontaneous arthritis. Pathologic analysis revealed no differences between etanercept-treated and phosphate buffered saline-treated mice. TNFalpha-positive cells were observed in the synovium, in vessel-associated cells, in fibrocartilage, and in new cartilage. Activation of Smad signaling was observed in earlier stages of disease than was active NF-kappaB signaling. TNFalpha inhibited chondrogenesis in the micromass model. CONCLUSION: Inhibition of TNF did not affect the severity and incidence of joint ankylosis in a mouse model of SpA. Therefore, the process of entheseal ankylosis may be independent of TNF. New tissue formation in SpA could be considered an additional and specific therapeutic target.",
keywords = "animals, ankylosis, antibodies, antirheumatic agents, bone morphogenetic proteins, cells, cultured, disease models, animal, disease progression, immunoglobulin G, inflammation, joints, male, mice, mice, inbred DBA, NF-kappa B, osteogenesis, receptors, tumor necrosis factor, severity of illness index, smad proteins, spondylarthritis, tumor necrosis factor-alpha",
author = "Lories, {Rik J. U.} and Inge Derese and {De Bari}, Cosimo and Luyten, {Frank P.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1002/art.22372",
language = "English",
volume = "56",
pages = "489--497",
journal = "Arthritis & Rheumatism",
issn = "0004-3591",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis

AU - Lories, Rik J. U.

AU - Derese, Inge

AU - De Bari, Cosimo

AU - Luyten, Frank P.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - OBJECTIVE: To study the relationship between inflammation and remodeling by inhibiting tumor necrosis factor alpha (TNFalpha) in male DBA/1 mice with spontaneous arthritis, a model of spondylarthritis (SpA). METHODS: TNFalpha was inhibited using etanercept, a soluble TNF receptor. The efficacy of the dose used (25 micro g/mouse) was confirmed in methylated bovine serum albumin (mBSA)-induced monarthritis, a model of inflammation-driven joint destruction. Male DBA/1 mice with spontaneous arthritis were caged together from the age of 10 weeks onward and were treated twice weekly with etanercept. The incidence and clinical severity of disease were recorded. Mice were killed at age 25 weeks, and histomorphologic analysis was performed. The presence of TNFalpha, NF-kappaB, and Smad signaling was studied using immunohistochemistry. Entheseal endochondral bone formation was modeled using micromass cultures of periosteal cells. RESULTS: Etanercept inhibited mouse TNFalpha in vitro and in vivo. Etanercept treatment of mBSA-induced arthritis had a significant effect on the severity of disease. Etanercept did not affect the incidence or severity of spontaneous arthritis. Pathologic analysis revealed no differences between etanercept-treated and phosphate buffered saline-treated mice. TNFalpha-positive cells were observed in the synovium, in vessel-associated cells, in fibrocartilage, and in new cartilage. Activation of Smad signaling was observed in earlier stages of disease than was active NF-kappaB signaling. TNFalpha inhibited chondrogenesis in the micromass model. CONCLUSION: Inhibition of TNF did not affect the severity and incidence of joint ankylosis in a mouse model of SpA. Therefore, the process of entheseal ankylosis may be independent of TNF. New tissue formation in SpA could be considered an additional and specific therapeutic target.

AB - OBJECTIVE: To study the relationship between inflammation and remodeling by inhibiting tumor necrosis factor alpha (TNFalpha) in male DBA/1 mice with spontaneous arthritis, a model of spondylarthritis (SpA). METHODS: TNFalpha was inhibited using etanercept, a soluble TNF receptor. The efficacy of the dose used (25 micro g/mouse) was confirmed in methylated bovine serum albumin (mBSA)-induced monarthritis, a model of inflammation-driven joint destruction. Male DBA/1 mice with spontaneous arthritis were caged together from the age of 10 weeks onward and were treated twice weekly with etanercept. The incidence and clinical severity of disease were recorded. Mice were killed at age 25 weeks, and histomorphologic analysis was performed. The presence of TNFalpha, NF-kappaB, and Smad signaling was studied using immunohistochemistry. Entheseal endochondral bone formation was modeled using micromass cultures of periosteal cells. RESULTS: Etanercept inhibited mouse TNFalpha in vitro and in vivo. Etanercept treatment of mBSA-induced arthritis had a significant effect on the severity of disease. Etanercept did not affect the incidence or severity of spontaneous arthritis. Pathologic analysis revealed no differences between etanercept-treated and phosphate buffered saline-treated mice. TNFalpha-positive cells were observed in the synovium, in vessel-associated cells, in fibrocartilage, and in new cartilage. Activation of Smad signaling was observed in earlier stages of disease than was active NF-kappaB signaling. TNFalpha inhibited chondrogenesis in the micromass model. CONCLUSION: Inhibition of TNF did not affect the severity and incidence of joint ankylosis in a mouse model of SpA. Therefore, the process of entheseal ankylosis may be independent of TNF. New tissue formation in SpA could be considered an additional and specific therapeutic target.

KW - animals

KW - ankylosis

KW - antibodies

KW - antirheumatic agents

KW - bone morphogenetic proteins

KW - cells, cultured

KW - disease models, animal

KW - disease progression

KW - immunoglobulin G

KW - inflammation

KW - joints

KW - male

KW - mice

KW - mice, inbred DBA

KW - NF-kappa B

KW - osteogenesis

KW - receptors, tumor necrosis factor

KW - severity of illness index

KW - smad proteins

KW - spondylarthritis

KW - tumor necrosis factor-alpha

U2 - 10.1002/art.22372

DO - 10.1002/art.22372

M3 - Article

VL - 56

SP - 489

EP - 497

JO - Arthritis & Rheumatism

JF - Arthritis & Rheumatism

SN - 0004-3591

IS - 2

ER -